Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phellopterin
- Development stage
- Unknown
- Lead developer
- The Chinese University of Hong Kong
01
Overview
Phellopterin: sourced facts only. name: "Mechanistically, cellular thermal shift assays combined with luciferase reporter assays confirmed that phellopterin could bind to GR and inhibit GR activation in vitro." [PMID:41765273]; target: "Mechanistically, cellular thermal shift assays combined with luciferase reporter assays confirmed that phellopterin could bind to GR and inhibit GR activation in vitro." [PMID:41765273]; developer: "Shenzhen Key Laboratory of Steroid Drug Discovery and Development, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China." [PMID:41765273]; stage: "In vivo, phellopterin counteracted dexamethasone-driven hyperlipidemia and lipid accumulation in hepatocytes and adipocytes in C57BL/6J mice." [PMID:41765273]
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Phellopterin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phellopterin.